论文部分内容阅读
目的评价低分子肝素在急性脑梗死治疗中的疗效及安全性。方法选取2005年2月至2008年4月就诊于我院符合条件的急性脑梗死患者112例,随机分为治疗组与对照组,各56例,治疗组给予基础治疗+低分子肝素治疗,对照组给予基础治疗。结果治疗组总有效率为89.3%,对照组总有效率为75.0%,χ2=3.896,P<0.05,两组间差异有统计学意义。治疗组PT、APTT、BT及CT在治疗前后均无统计学意义(P>0.05)。结论低分子肝素治疗急性脑梗死有效,且较为安全。
Objective To evaluate the efficacy and safety of low molecular weight heparin in the treatment of acute cerebral infarction. Methods A total of 112 patients with acute cerebral infarction who were admitted to our hospital from February 2005 to April 2008 were randomly divided into treatment group and control group, with 56 cases in each group. The treatment group received basic therapy plus low molecular weight heparin, while the control group Group given basic treatment. Results The total effective rate was 89.3% in the treatment group and 75.0% in the control group (χ2 = 3.896, P <0.05). The difference between the two groups was statistically significant. The treatment group PT, APTT, BT and CT before and after treatment were not statistically significant (P> 0.05). Conclusion Low molecular weight heparin is effective and safe for the treatment of acute cerebral infarction.